ENRIQUETA FELIP
Hospital Vall d'Hebron, Universidad de Navarra IESE Business School - Madrid Campus, Universitat Autònoma de Barcelona
Research areas: Medicine · Pulmonary and Respiratory Medicine · Lung Cancer Treatments and Mutations · Lung Cancer Diagnosis and Treatment · Lung Cancer Research Studies
0000-0002-7620-0098
About
Enriqueta Felip is Head of the Thoracic Cancer Group within the Oncology Department of the Vall d'Hebron University Hospital, Barcelona, Spain, and is also Associate Professor at the Autonomous University of Barcelona (UAB). Enriqueta Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology. Professor Felip is in charge of lung cancer management, and is responsible for lung cancer trials undertaken by the Oncology Department. Current research lines include the optimization of chemotherapy in early-stage disease, evaluation of new drugs, and the use of pharmacogenomic approaches.
She is currently a member of the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón; GECP), the Spanish Society of Medical Oncology (Sociedad Española de Oncología Medíca; SEOM), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC). She is a member of the Scientific Executive Committee of the National Lung Cancer Partnership, and is also the coordinator of lung cancer program of the European School of Oncology (ESO). She is author of many peer-reviewed articles and book chapters relating to the field of lung cancer.
Dr. Enriqueta Felip’s strategic goals are:
- Optimization of multidisciplinary treatment in patients with stage I-III cancer Advance personalized medicine for lung cancer patients through translational research.
- Contribute to early drug development and matched therapies for thoracic tumors.
- Optimize novel treatment approaches (immunotherapy) for the management of patients with thoracic malignancies.
- Active intervention in the fight against smoking.
Her current objectives are:
- Implement the determination ALK translocationStudy the efficacy of PI3K/mTOR inhibitors in patients with lung cancer resistant to EGFRTKIs.
- Study the efficacy of PARP inhibitors in lung cancer.
- Analyze the epidemiologic/clinical characteristics of women diagnosed with lung cancer.
- Play an active role in organizing a European consensus meeting on lung cancer
Employment
-
Hospital Vall d'Hebron Head Thoracic Oncology Unit (After Competitive Exam)2011 - Present
-
Hospital Vall d'Hebron Head of Department (-PROVISIONAL-)2007 - 2011
-
Hospital Vall d'Hebron Senior Clinical Attending Physician2003 - 2007
-
Hospital Vall d'Hebron Clinical Attending Physician1992 - 2003
-
Hospital Vall d'Hebron Resident in Medical Oncology1988 - 1992
Education
-
Universidad de Navarra IESE Business School - Madrid Campus "Programa de Alta Dirección en Instituciones Sanitarias"2014 - 2014
-
Universitat Autònoma de Barcelona Speciality in Medical Oncology1991 - Present
-
Universitat Autònoma de Barcelona Degree in Medicine and Surgery1981 - 1987
Projects & Funding
-
ESMO Women for Oncology Award European Society for Medical Oncology2015 - Present
-
"Next generation molecular platforms to identify new therapeutics targets and prognostic markers neglected types of lung cancer". Fundación Científica Asociación Española Contra el Cáncer2014 - 2019
-
"SPECTAlung: Screening Patients with Thoracic tumors for Efficient Clinical Trial Access" European Organisation for Research and Treatment of Cancer2014 - 2018
-
BARCELONA OFFCIAL SCHOOL OF MEDICINE "Professional Excellence Award" Col.legi Ofical de Metges de Barcelona2012 - Present
-
"Dr. Robert Ginsberg Award Lectureship in Surgery 2009 to Enriqueta Felip" (IASLC) International Association for the Study of Lung Cancer2009 - Present
-
ESMO Best Poster Award: "Epidermal Growth Factor receptor (EGFR) expression correlation between diagnostic and post platinum-based progression samples of non-small-cell lung cancer (NSCLC) patients". European Society for Medical Oncology2004 - Present
-
"Xenoinjertos ortotópicos derivados de pacientes como herramienta para el estudio de mecanismos de resistencia adquirida en cánceres de pulmón dependientes de oncogenes". Fundación Merck Salud
Publications (389)
- Data from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Figure S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Figure S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Figure S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Methods1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Table S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Table S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Table S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Table S4 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Table S5 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Supplementary Table S6 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study Save
- Data from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save
- Figure 1 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save
- Figure 2 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save
- Figure 3 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save
- Figure 4 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save
- Figure 5 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save
- Figure 6 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save
- Supplementary Figure S1 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study Save